Pages that link to "Q34818378"
Jump to navigation
Jump to search
The following pages link to Treatment of acute myeloid leukemia: state-of-the-art and future directions (Q34818378):
Displaying 10 items.
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia (Q33392683) (← links)
- Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. (Q34162844) (← links)
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. (Q34193534) (← links)
- Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems (Q35210617) (← links)
- Invasive aspergillosis in patients with hematologic malignancies. (Q35616161) (← links)
- Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine (Q35847836) (← links)
- Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update (Q36194631) (← links)
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations (Q36481950) (← links)
- Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients. (Q53591036) (← links)
- Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study (Q63241100) (← links)